Opexa Therapeutics Company Profile (NASDAQ:OPXA)

About Opexa Therapeutics

Opexa Therapeutics logoOpexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology. The Company's product candidates include Tcelna and OPX-212. Tcelna is an autologous T-cell immunotherapy that is being developed for the treatment of secondary progressive MS (SPMS) and is tailored to each patient's immune response profile to myelin. Tcelna is designed to reduce the number and/or functional activity of specific subsets of myelin-reactive T-cells (MRTCs) known to attack myelin. Tcelna is manufactured using its method for the production of an autologous T-cell product. In addition to the ongoing clinical development of Tcelna, the Company is developing OPX-212 as an autologous T-cell immunotherapy for the treatment of NMO.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OPXA
  • CUSIP:
Key Metrics:
  • Previous Close: $1.10
  • 50 Day Moving Average: $0.97
  • 200 Day Moving Average: $2.33
  • 52-Week Range: $7,141,000.00 - $0.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.44
  • P/E Growth: 0.00
  • Market Cap: $7.86M
  • Outstanding Shares: 7,141,000
  • Beta: 2.04
Profitability:
  • Net Margins: -297.83%
  • Return on Equity: -126.03%
  • Return on Assets: -81.10%
Debt:
  • Current Ratio: 2.12%
  • Quick Ratio: 2.12%
Additional Links:
Companies Related to Opexa Therapeutics:

Analyst Ratings

Consensus Ratings for Opexa Therapeutics (NASDAQ:OPXA) (?)
Ratings Breakdown: 3 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $11.67 (960.61% upside)

Analysts' Ratings History for Opexa Therapeutics (NASDAQ:OPXA)
Show:
DateFirmActionRatingPrice TargetDetails
10/28/2016Maxim GroupDowngradeBuy -> HoldView Rating Details
10/28/2016Chardan CapitalDowngradeBuy -> NeutralView Rating Details
10/28/2016AegisDowngradeBuy -> HoldView Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for Opexa Therapeutics (NASDAQ:OPXA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/11/2016        
11/14/2016Q3 2016($0.25)($0.28)ViewN/AView Earnings Details
8/11/2016Q216($0.23)($0.30)ViewListenView Earnings Details
5/12/2016Q116($0.35)($0.31)ViewListenView Earnings Details
3/15/2016Q415($0.50)($2.05)ViewListenView Earnings Details
11/10/2015Q315($2.48)($0.42)ViewN/AView Earnings Details
8/12/2015Q215($0.08)($0.07)ViewListenView Earnings Details
5/12/2015Q1($0.15)($0.12)ViewListenView Earnings Details
2/23/2015($0.14)($0.12)ViewN/AView Earnings Details
8/14/2014Q214($0.13)($0.15)ViewN/AView Earnings Details
5/14/2014Q114($0.13)($0.13)$0.22 million$0.35 millionViewN/AView Earnings Details
8/14/2013Q213($0.37)$0.35 millionViewN/AView Earnings Details
11/14/2012Q312($0.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Opexa Therapeutics (NASDAQ:OPXA)
Current Year EPS Consensus Estimate: $-1.12 EPS
Next Year EPS Consensus Estimate: $-0.32 EPS

Dividends

Dividend History for Opexa Therapeutics (NASDAQ:OPXA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Opexa Therapeutics (NASDAQ:OPXA)
Insider Ownership Percentage: 6.88%
Institutional Ownership Percentage: 7.07%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/18/2016Timothy C BarabeDirectorSell14,914$0.55$8,202.70View SEC Filing  
9/17/2014Timothy C BarabeDirectorBuy10,000$1.15$11,500.00View SEC Filing  
9/16/2014Neil K WarmaCEOBuy10,000$1.11$11,100.00View SEC Filing  
12/18/2013Karthik RadhakrishnanCFOBuy8,000$1.70$13,600.00View SEC Filing  
12/18/2013Scott B SeamanDirectorBuy30,000$1.70$51,000.00View SEC Filing  
8/8/2013Karthik RadhakrishnanCFOBuy50,000$1.50$75,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Opexa Therapeutics (NASDAQ:OPXA)
DateHeadline
News IconOpexa Therapeutics, Inc. (NASDAQ:OPXA) Trades Higher, 4 Hold Recommendations - OracleTimes (NASDAQ:OPXA)
oracletimes.com - February 17 at 8:16 AM
News IconTrader's Buzzers: Tenet Healthcare Corp. (NYSE:THC), Opexa Therapeutics, Inc. (NASDAQ:OPXA) - The Newburgh Press (NASDAQ:OPXA)
newburghpress.com - February 17 at 8:16 AM
News IconStocks on the Move: Opexa Therapeutics, Inc. (NASDAQ:OPXA), Mobile TeleSystems PJSC (NYSE:MBT) - The Newburgh Press (NASDAQ:OPXA)
newburghpress.com - February 17 at 8:16 AM
News IconMarket Scout: Checking the Levels for Opexa Therapeutics Inc. (OPXA) - Davidson Register (NASDAQ:OPXA)
davidsonregister.com - February 10 at 8:01 PM
News IconTechnical Indicator Review on Shares of Opexa Therapeutics Inc. (OPXA) - Piedmont Register (NASDAQ:OPXA)
piedmontregister.com - February 9 at 12:59 AM
biz.yahoo.com logoOPEXA THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisitio (NASDAQ:OPXA)
biz.yahoo.com - February 8 at 7:58 PM
News IconInvestor Corner: Checking the Charts for Opexa Therapeutics Inc. (OPXA) - Rives Journal (NASDAQ:OPXA)
rivesjournal.com - February 8 at 1:11 AM
News IconOpexa Therapeutics, Inc. (NASDAQ:OPXA) hit its 52 Week low of $0.5 on Nov 15, 2016 - The Newburgh Press (NASDAQ:OPXA)
newburghpress.com - February 8 at 1:10 AM
News IconMy Watchlist for Monday, February 06 (NASDAQ:OPXA)
ac-investor.blogspot.com - February 4 at 7:04 PM
News IconTrading Sheet: Tracking Technicals for Opexa Therapeutics Inc. (OPXA) - Sherwood Daily (NASDAQ:OPXA)
sherwooddaily.com - February 4 at 5:53 AM
News IconMarket Review: Indicator Watch for Opexa Therapeutics Inc. (OPXA) - Sherwood Daily (NASDAQ:OPXA)
sherwooddaily.com - February 3 at 12:59 AM
News IconADX in View on Shares of Opexa Therapeutics Inc. (OPXA) - Sherwood Daily (NASDAQ:OPXA)
sherwooddaily.com - February 1 at 8:13 PM
News IconOpexa Therapeutics (Nasdaq: OPXA) Announces Lease Assignment Annual Savings - StockNewsUnion (NASDAQ:OPXA)
stocknewsunion.com - February 1 at 8:13 PM
finance.yahoo.com logoOpexa Facility Becomes Foundation for Contract Manufacturing and Development Organization for Cellular Therapies (NASDAQ:OPXA)
finance.yahoo.com - February 1 at 8:13 PM
feeds.reuters.com logoBRIEF-Opexa Therapeutics Inc further reduces its workforce (NASDAQ:OPXA)
feeds.reuters.com - February 1 at 8:27 AM
News IconChart Inspection on Shares of Opexa Therapeutics Inc. (OPXA) - Sherwood Daily (NASDAQ:OPXA)
sherwooddaily.com - January 31 at 8:02 PM
News IconEquity Focus: Indicator Check on Shares of Opexa Therapeutics Inc. (OPXA) - Sherwood Daily (NASDAQ:OPXA)
sherwooddaily.com - January 31 at 6:03 AM
News IconBargain Hunters Should Take a Look at Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Prospect Journal (NASDAQ:OPXA)
prospectjournal.com - January 31 at 6:03 AM
News IconNarrowing in on Chart Levels for Opexa Therapeutics Inc. (OPXA) - Sherwood Daily (NASDAQ:OPXA)
sherwooddaily.com - January 27 at 12:16 AM
News IconRSI Review on Shares of Opexa Therapeutics Inc. (OPXA) - Sherwood Daily (NASDAQ:OPXA)
sherwooddaily.com - January 26 at 4:19 AM
News IconShares in View: Opexa Therapeutics Inc. (OPXA) - Sherwood Daily (NASDAQ:OPXA)
sherwooddaily.com - January 21 at 7:29 AM
News IconMoving Averages in Focus on Shares of Opexa Therapeutics Inc. (OPXA) - Sherwood Daily (NASDAQ:OPXA)
sherwooddaily.com - January 20 at 4:43 AM
News IconBounding Shares, What's Next for Opexa Therapeutics, Inc ... - Prospect Journal (NASDAQ:OPXA)
prospectjournal.com - January 20 at 4:43 AM
News IconTracking CCI Levels on Shares of Opexa Therapeutics Inc. (OPXA) - Sherwood Daily (NASDAQ:OPXA)
sherwooddaily.com - January 18 at 8:53 AM
istreetwire.com logoStocks Trend Analysis: Clovis Oncology, Inc. (CLVS) Opexa ... - iStreetWire (NASDAQ:OPXA)
istreetwire.com - January 18 at 8:53 AM
News IconOpexa Therapeutics Inc (NASDAQ:OPXA) Is A Buyout Target; But Not For Its Pipeline - Insider Financial (NASDAQ:OPXA)
www.insiderfinancial.com - January 18 at 8:53 AM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Opexa ... - Wall Street Beacon (NASDAQ:OPXA)
wsbeacon.com - January 15 at 8:15 AM
News IconMomentum Stocks Try To Beat Analysts' Views: Opexa Therapeutics ... - Street Wise Report (press release) (blog) (NASDAQ:OPXA)
streetwisereport.com - January 14 at 7:08 PM
News IconDelving into Shares of Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Prospect Journal (NASDAQ:OPXA)
prospectjournal.com - January 12 at 5:44 AM
News IconBoom or Bust? Is there any value in Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Prospect Journal (NASDAQ:OPXA)
prospectjournal.com - January 11 at 12:56 AM
News IconLevels in View for Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Wall Street Beacon (NASDAQ:OPXA)
wsbeacon.com - January 11 at 12:56 AM
News IconOpexa Therapeutics, Inc. (OPXA) Valuation According To Analysts - UK Market News (NASDAQ:OPXA)
www.ukmarketnews.co.uk - January 10 at 12:48 AM
News IconCheap Stock Alert on Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Prospect Journal (NASDAQ:OPXA)
prospectjournal.com - January 10 at 12:48 AM
News IconOpexa Therapeutics Inc OPXA Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:OPXA)
www.bioportfolio.com - January 9 at 7:45 PM
News IconOpexa Therapeutics Inc OPXA Medical Equipment Deals and Alliances Profile Prices from USD $250 (NASDAQ:OPXA)
www.bioportfolio.com - January 8 at 6:44 PM
News IconInvestor Hub: Looking at Shares of Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Wall Street Beacon (NASDAQ:OPXA)
wsbeacon.com - January 7 at 11:17 PM
News IconInvestor Update: Looking at Shares of Opexa Therapeutics, Inc ... - Wall Street Beacon (NASDAQ:OPXA)
wsbeacon.com - January 5 at 11:47 PM
News IconPeering into Recent Action from Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Prospect Journal (NASDAQ:OPXA)
prospectjournal.com - December 30 at 7:26 PM
News IconCompany Stock Watch: Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Wall Street Beacon (NASDAQ:OPXA)
wsbeacon.com - December 30 at 12:01 AM
capitalcube.com logoETFs with exposure to Opexa Therapeutics, Inc. : December 23, 2016 (NASDAQ:OPXA)
www.capitalcube.com - December 23 at 7:12 PM
News IconCompany Review: Narrowing in on Shares of Opexa Therapeutics ... - Wall Street Beacon (NASDAQ:OPXA)
wsbeacon.com - December 23 at 6:31 AM
News IconMy Watchlist for Friday, December 23 (NASDAQ:OPXA)
ac-investor.blogspot.com - December 22 at 7:23 PM
News IconNotable Stock For Under $5: Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Prospect Journal (NASDAQ:OPXA)
prospectjournal.com - December 20 at 11:39 PM
News IconMarket Focus: Zooming in on Shares of Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Business Daily Leader (NASDAQ:OPXA)
businessdailyleader.com - December 20 at 1:28 PM
News IconInvestor Wire: Keeping an Eye on Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Wall Street Beacon (NASDAQ:OPXA)
wsbeacon.com - December 20 at 1:28 PM
News IconStock Levels in View for Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Highland Digest (NASDAQ:OPXA)
highlanddigest.com - December 18 at 7:21 PM
News IconStock Check on Opexa Therapeutics, Inc. (NASDAQ:OPXA) – Wall ... - Wall Street Beacon (NASDAQ:OPXA)
wsbeacon.com - December 18 at 5:52 AM
News IconStock Roaring Higher Pre-Bell: Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Prospect Journal (NASDAQ:OPXA)
prospectjournal.com - December 15 at 5:49 AM
News IconInvestor View: Looking at Shares of Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Wall Street Beacon (NASDAQ:OPXA)
wsbeacon.com - December 15 at 5:49 AM
capitalcube.com logoETFs with exposure to Opexa Therapeutics, Inc. : December 12, 2016 (NASDAQ:OPXA)
www.capitalcube.com - December 12 at 7:11 PM

Social

What is Opexa Therapeutics' stock symbol?

Opexa Therapeutics trades on the NASDAQ under the ticker symbol "OPXA."

Where is Opexa Therapeutics' stock going? Where will Opexa Therapeutics' stock price be in 2017?

3 brokerages have issued twelve-month price objectives for Opexa Therapeutics' shares. Their forecasts range from $6.00 to $18.00. On average, they anticipate Opexa Therapeutics' stock price to reach $11.67 in the next twelve months.

When will Opexa Therapeutics announce their earnings?

Opexa Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, November, 11th 2016.

What are analysts saying about Opexa Therapeutics stock?

Here are some recent quotes from research analysts about Opexa Therapeutics stock:

  • According to Zacks Investment Research, "Opexa Therapeutics, Inc. develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin, a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for type one diabetes. " (10/26/2016)

  • Maxim Group analysts commented, "Opexa reported 2Q16 with a net loss of $2.1M. The company ended the period with ~$8M in cash, sufficient runway through what we see as not just one, but two inflection points. Tcelna POC data in SPMS are expected by early 4Q, and then the decision by Merck Serono on whether to opt in and go pivotal (phase III), fund a redo" phase II study, or walk away will occur (this could take up to 60 days after data are announced)." (8/12/2016)

Who owns Opexa Therapeutics stock?

Opexa Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Albert and Margaret Alkek Foundation (0.73%).

How do I buy Opexa Therapeutics stock?

Shares of Opexa Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Opexa Therapeutics stock cost?

One share of Opexa Therapeutics stock can currently be purchased for approximately $1.10.

Opexa Therapeutics (NASDAQ:OPXA) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Opexa Therapeutics (NASDAQ:OPXA)

Earnings History Chart

Earnings by Quarter for Opexa Therapeutics (NASDAQ:OPXA)

Dividend History Chart

Dividend Payments by Quarter for Opexa Therapeutics (NASDAQ:OPXA)

Last Updated on 2/20/2017 by MarketBeat.com Staff